Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients.
Kiki Waeijen-SmitMieke CrutsenSpencer KeeneMarc MiravitllesErnesto CrisafulliAntoní TorresChristian MuellerPhilipp SchuetzThomas J RingbækFabio FabbianEvgeni MekovTimothy H HarriesChung-Tat LunBegüm ErganCristóbal EstebanJosé María QuintanaJosé Luis López-CamposCatherina L ChangRobert J HancoxEskandarain ShafuddinHollie EllisChrister JanssonCharlotte Suppli UlrikGunnar GudmundssonDanny EpsteinJosé DominguezAlicia LacomaChristian Robert OsadnikInmaculada AliaFrancesco SpannellaZuhal KarakurtHossein MehravaranCecile UtensMartijn D de KruifFanny Wai-San KoSamuel P TretheweyAlice Margaret TurnerDragos BumbăceaPatrick Brian MurphyKristina VermeerschShani Zilberman-ItskovichJohn SteerCarlos EchevarriaStephen C BourkeNicholas David LaneJordi de BatlleRoy T M SprootenRichard E K RussellPaola FaverioJane L CrossHendrik J PrinsMartijn A. SpruitSami Olavi SimonsSarah Houben-WilkeFrits M E FranssenPublished in: ERJ open research (2024)
This IPDMA stresses the poor outcomes and high heterogeneity of ECOPD-related hospitalisation across the world. Whilst global standardisation of the management and follow-up of ECOPD-related hospitalisation should be at the heart of future implementation research, policy makers should focus on reimbursing evidence-based therapies that decrease (recurrent) ECOPD.
Keyphrases
- chronic obstructive pulmonary disease
- healthcare
- end stage renal disease
- public health
- ejection fraction
- primary care
- chronic kidney disease
- newly diagnosed
- single cell
- type diabetes
- prognostic factors
- peritoneal dialysis
- coronary artery disease
- adipose tissue
- metabolic syndrome
- cardiovascular disease
- quality improvement
- intensive care unit
- risk factors
- patient reported outcomes